Gender differences in the effects of peroxisome proliferator-activated receptor γ2 gene polymorphisms on metabolic adversity in patients with schizophrenia or schizoaffective disorder

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 35, Issue 1, 2011, Pages 239-245

  Chen, Chun Hsin ^a,b   Lu, Mong Liang ^a,b   Kuo, Po Hsiu ^c   Chen, Po Yu ^d   Chiu, Chih Chiang ^b,d   Kao, Chung Feng ^c   Huang, Ming Chyi ^b,d  

^a TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^b TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^c NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^d TAIPEI CITY HOSPITAL   (Taiwan)

Author keywords

Gender difference; Metabolic adversity; Peroxisome proliferator activated receptor 2; Polymorphism; Schizophrenia

Indexed keywords

HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA 2;

ABDOMINAL OBESITY; ADULT; ARTICLE; BODY WEIGHT; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DNA POLYMORPHISM; FEMALE; GENE FREQUENCY; GENE FUNCTION; GENOTYPE; HAPLOTYPE; HUMAN; HYPERGLYCEMIA; HYPERTENSION; INSULIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; METABOLIC DISORDER; OBESITY; RISK ASSESSMENT; RISK FACTOR; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SEX DIFFERENCE; SYSTOLIC BLOOD PRESSURE; WAIST CIRCUMFERENCE;

ADULT; ALANINE; FEMALE; GENE FREQUENCY; GENOTYPE; HUMANS; MALE; METABOLIC DISEASES; METABOLIC SYNDROME X; MIDDLE AGED; OBESITY; POLYMORPHISM, GENETIC; PPAR GAMMA; PROLINE; PSYCHIATRIC STATUS RATING SCALES; PSYCHOTIC DISORDERS; SCHIZOPHRENIA; SEX CHARACTERISTICS;

EID: 78650931873     PISSN: 02785846     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pnpbp.2010.11.014     Document Type: Article

References (48)

1. Allison D.B., Mentore J.L., Heo M., Chandler L.P., Cappelleri J.C., Infante M.C., et al. Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry 1999, 156:1686-1696.
2. Beamer B.A., Negri C., Yen C.J., Gavrilova O., Rumberger J.M., Durcan M.J., et al. Chromosomal localization and partial genomic structure of the human peroxisome proliferator activated receptor-gamma (hPPAR gamma) gene. Biochem Biophys Res Commun 1997, 233:756-759.
3. Ben Ali S., Ben Yahia F., Sediri Y., Kallel A., Ftouhi B., Feki M., et al. Gender-specific effect of Pro12Ala polymorphism in peroxisome proliferator-activated receptor gamma-2 gene on obesity risk and leptin levels in a Tunisian population. Clin Biochem 2009, 42:1642-1647.
4. Bobes J., Arango C., Aranda P., Carmena R., Garcia-Garcia M., Rejas J. Cardiovascular and metabolic risk in outpatients with schizophrenia treated with antipsychotics: results of the CLAMORS Study. Schizophr Res 2007, 90:162-173.
5. Buchanan T.A., Meehan W.P., Jeng Y.Y., Yang D., Chan T.M., Nadler J.L., et al. Blood pressure lowering by pioglitazone. Evidence for a direct vascular effect. J Clin Invest 1995, 96:354-360.
6. Chagnon Y.C., Merette C., Bouchard R.H., Emond C., Roy M.A., Maziade M. A genome wide linkage study of obesity as secondary effect of antipsychotics in multigenerational families of eastern Quebec affected by psychoses. Mol Psychiatry 2004, 9:1067-1074.
7. Cohn T., Prud'homme D., Streiner D., Kameh H., Remington G. Characterizing coronary heart disease risk in chronic schizophrenia: high prevalence of the metabolic syndrome. Can J Psychiatry 2004, 49:753-760.
8. De Hert M., van Eyck D., De Nayer A. Metabolic abnormalities associated with second generation antipsychotics: fact or fiction Development of guidelines for screening and monitoring. Int Clin Psychopharmacol 2006, 21(Suppl 2):S11-S15.
9. Deeb S.S., Fajas L., Nemoto M., Pihlajamaki J., Mykkanen L., Kuusisto J., et al. A Pro12Ala substitution in PPARgamma2 associated with decreased receptor activity, lower body mass index and improved insulin sensitivity. Nat Genet 1998, 20:284-287.
10. Desvergne B., Wahli W. Peroxisome proliferator-activated receptors: nuclear control of metabolism. Endocr Rev 1999, 20:649-688.
11. Francis G.A., Fayard E., Picard F., Auwerx J. Nuclear receptors and the control of metabolism. Annu Rev Physiol 2003, 65:261-311.
12. Frederiksen L., Brodbaek K., Fenger M., Jorgensen T., Borch-Johnsen K., Madsbad S., et al. Comment: studies of the Pro12Ala polymorphism of the PPAR-gamma gene in the Danish MONICA cohort: homozygosity of the Ala allele confers a decreased risk of the insulin resistance syndrome. J Clin Endocrinol Metab 2002, 87:3989-3992.
13. Gonzalez Sanchez J.L., Serrano Rios M., Fernandez Perez C., Laakso M., Martinez Larrad M.T. Effect of the Pro12Ala polymorphism of the peroxisome proliferator-activated receptor gamma-2 gene on adiposity, insulin sensitivity and lipid profile in the Spanish population. Eur J Endocrinol 2002, 147:495-501.
14. Gouda H.N., Sagoo G.S., Harding A.H., Yates J., Sandhu M.S., Higgins J.P. The association between the peroxisome proliferator-activated receptor-gamma2 (PPARG2) Pro12Ala gene variant and type 2 diabetes mellitus: a HuGE review and meta-analysis. Am J Epidemiol 2010, 171:645-655.
15. Gregoor J.G., van der Weide J., Mulder H., Cohen D., van Megen H.J., Egberts A.C., et al. Polymorphisms of the LEP- and LEPR gene and obesity in patients using antipsychotic medication. J Clin Psychopharmacol 2009, 29:21-25.
16. Hagg S., Lindblom Y., Mjorndal T., Adolfsson R. High prevalence of the metabolic syndrome among a Swedish cohort of patients with schizophrenia. Int Clin Psychopharmacol 2006, 21:93-98.
17. Herken H., Erdal M., Aydin N., Sengul C., Karadag F., Barlas O., et al. The association of olanzapine-induced weight gain with peroxisome proliferator-activated receptor-gamma2 Pro12Ala polymorphism in patients with schizophrenia. DNA Cell Biol 2009, 28:515-519.
18. Hsueh W.A., Bruemmer D. Peroxisome proliferator-activated receptor gamma: implications for cardiovascular disease. Hypertension 2004, 43:297-305.
19. Huang M.C., Lu M.L., Tsai C.J., Chen P.Y., Chiu C.C., Jian D.L., et al. Prevalence of metabolic syndrome among patients with schizophrenia or schizoaffective disorder in Taiwan. Acta Psychiatr Scand 2009, 120:274-280.
20. Kotchen T.A. Attenuation of hypertension by insulin-sensitizing agents. Hypertension 1996, 28:219-223.
21. Lakka H.M., Laaksonen D.E., Lakka T.A., Niskanen L.K., Kumpusalo E., Tuomilehto J., et al. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA 2002, 288:2709-2716.
22. Lei H.H., Chen M.H., Yang W.S., Chiu M.C., Chen M.C., Tai T.Y., et al. Peroxisome proliferator-activated receptor gamma 2 Pro12Ala gene variant is strongly associated with larger body mass in the Taiwanese. Metabolism 2000, 49:1267-1270.
23. Liu D., Hua Q., Liu L., Guo J. Association of peroxisome proliferator-activated receptor gene Pro12Ala and C161T polymorphisms with metabolic syndrome. Circ J 2008, 72:551-557.
24. Masugi J., Tamori Y., Mori H., Koike T., Kasuga M. Inhibitory effect of a proline-to-alanine substitution at codon 12 of peroxisome proliferator-activated receptor-gamma 2 on thiazolidinedione-induced adipogenesis. Biochem Biophys Res Commun 2000, 268:178-182.
25. Matthews D.R., Hosker J.P., Rudenski A.S., Naylor B.A., Treacher D.F., Turner R.C. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985, 28:412-419.
26. McCarthy J.J., Somji A., Weiss L.A., Steffy B., Vega R., Barrett-Connor E., et al. Polymorphisms of the scavenger receptor class B member 1 are associated with insulin resistance with evidence of gene by sex interaction. J Clin Endocrinol Metab 2009, 94:1789-1796.
27. Moon M.K., Cho Y.M., Jung H.S., Park Y.J., Yoon K.H., Sung Y.A., et al. Genetic polymorphisms in peroxisome proliferator-activated receptor gamma are associated with Type 2 diabetes mellitus and obesity in the Korean population. Diabet Med 2005, 22:1161-1166.
28. Morini E., Tassi V., Capponi D., Ludovico O., Dallapiccola B., Trischitta V., et al. Interaction between PPARgamma2 variants and gender on the modulation of body weight. Obesity (Silver Spring) 2008, 16:1467-1470.
29. Mukherjee R., Jow L., Croston G.E., Paterniti J.R. Identification, characterization, and tissue distribution of human peroxisome proliferator-activated receptor (PPAR) isoforms PPARgamma2 versus PPARgamma1 and activation with retinoid X receptor agonists and antagonists. J Biol Chem 1997, 272:8071-8076.
30. Muller D.J., Muglia P., Fortune T., Kennedy J.L. Pharmacogenetics of antipsychotic-induced weight gain. Pharmacol Res 2004, 49:309-329.
31. Newcomer J.W. Antipsychotic medications: metabolic and cardiovascular risk. J Clin Psychiatry 2007, 68(Suppl 4):8-13.
32. Ogihara T., Rakugi H., Ikegami H., Mikami H., Masuo K. Enhancement of insulin sensitivity by troglitazone lowers blood pressure in diabetic hypertensives. Am J Hypertens 1995, 8:316-320.
33. Paracchini V., Pedotti P., Taioli E. Genetics of leptin and obesity: a HuGE review. Am J Epidemiol 2005, 162:101-114.
34. Radha V., Vimaleswaran K.S., Babu H.N., Abate N., Chandalia M., Satija P., et al. Role of genetic polymorphism peroxisome proliferator-activated receptor-gamma2 Pro12Ala on ethnic susceptibility to diabetes in South-Asian and Caucasian subjects: Evidence for heterogeneity. Diab Care 2006, 29:1046-1051.
35. Rhee E.J., Oh K.W., Lee W.Y., Kim S.Y., Oh E.S., Baek K.H., et al. Effects of two common polymorphisms of peroxisome proliferator-activated receptor-gamma gene on metabolic syndrome. Arch Med Res 2006, 37:86-94.
36. Rosen E.D., Spiegelman B.M. PPARgamma: a nuclear regulator of metabolism, differentiation, and cell growth. J Biol Chem 2001, 276:37731-37734.
37. Ross R. Atherosclerosis-an inflammatory disease. N Engl J Med 1999, 340:115-126.
38. Sun J., Kuo P.H., Riley B.P., Kendler K.S., Zhao Z. Candidate genes for schizophrenia: a survey of association studies and gene ranking. Am J Med Genet B Neuropsychiatr Genet 2008, 147B:1173-1181.
39. Suvisaari J.M., Saarni S.I., Perala J., Suvisaari J.V., Harkanen T., Lonnqvist J., et al. Metabolic syndrome among persons with schizophrenia and other psychotic disorders in a general population survey. J Clin Psychiatry 2007, 68:1045-1055.
40. Tan C.E., Ma S., Wai D., Chew S.K., Tai E.S. Can we apply the National Cholesterol Education Program Adult Treatment Panel definition of the metabolic syndrome to Asians?. Diab Care 2004, 27:1182-1186.
41. Tonjes A., Scholz M., Loeffler M., Stumvoll M. Association of Pro12Ala polymorphism in peroxisome proliferator-activated receptor gamma with Pre-diabetic phenotypes: meta-analysis of 57 studies on nondiabetic individuals. Diab Care 2006, 29:2489-2497.
42. Valve R., Sivenius K., Miettinen R., Pihlajamaki J., Rissanen A., Deeb S.S., et al. Two polymorphisms in the peroxisome proliferator-activated receptor-gamma gene are associated with severe overweight among obese women. J Clin Endocrinol Metab 1999, 84:3708-3712.
43. Vidal H. Gene expression in visceral and subcutaneous adipose tissues. Ann Med 2001, 33:547-555.
44. Vidal-Puig A.J., Considine R.V., Jimenez-Linan M., Werman A., Pories W.J., Caro J.F., et al. Peroxisome proliferator-activated receptor gene expression in human tissues. Effects of obesity, weight loss, and regulation by insulin and glucocorticoids. J Clin Invest 1997, 99:2416-2422.
45. Weiss L.A., Pan L., Abney M., Ober C. The sex-specific genetic architecture of quantitative traits in humans. Nat Genet 2006, 38:218-222.
46. Wilson P.W., D'Agostino R.B., Parise H., Sullivan L., Meigs J.B. Metabolic syndrome as a precursor of cardiovascular disease and type 2 diabetes mellitus. Circulation 2005, 112:3066-3072.
47. Wu M.K., Wang C.K., Bai Y.M., Huang C.Y., Lee S.D. Outcomes of obese, clozapine-treated inpatients with schizophrenia placed on a six-month diet and physical activity program. Psychiatr Serv 2007, 58:544-550.
48. Xiong C., Mou Y., Zhang J., Fu M., Chen Y.E., Akinbami M.A., et al. Impaired expression of PPAR gamma protein contributes to the exaggerated growth of vascular smooth muscle cells in spontaneously hypertensive rats. Life Sci 2005, 77:3037-3048.